Key result
Sustained activation of PDE5 by cGMP acts as a negative feedback mechanism in NO/cGMP signaling, allowing cells to adapt to available nitric oxide levels.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
This review elucidates the molecular mechanisms of NO-sensitive guanylyl cyclase and identifies PDE5-mediated cGMP degradation as a critical negative feedback loop in NO signaling.
Most effects of the signaling molecule nitric oxide (NO) are mediated by the stimulation of NO-sensitive guanylyl cyclase (GC) and the subsequent intracellular increase in cGMP. Two isoforms of NO-sensitive GC have been identified to date that share regulatory properties but differ in their subcellular localization; the more ubiquitously expressed alpha1beta1 heterodimer, and the alpha2beta1 isoform mainly expressed in brain. New activators of NO-sensitive GC have been identified which may have beneficial pharmacological effects in cardiovascular diseases. In intact cells, NO-induced cGMP signaling not only depends on cGMP formation but is also critically determined by the activity of the enzyme responsible for cGMP degradation, e.g. phosphodiesterase 5 (PDE5). Sustained activation of PDE5 by cGMP has been identified as the mechanism responsible for the recently observed feedback inhibition within NO/cGMP signaling. Moreover, tuning of PDE5 activity may also represent a regulatory link to mediate cross talk between NO-induced and natriuretic peptide-induced cGMP signaling in general.
No takes yet. Share an insight, caveat, or question.
M Pauler Florian (2005) reported a review. Sustained activation of PDE5 by cGMP acts as a negative feedback mechanism in NO/cGMP signaling, allowing cells to adapt to available nitric oxide levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: